Knight Therapeutics Inc. (TSX: GUD)

Market Cap	549.61M
Revenue (ttm)	348.64M
Net Income (ttm)	-30.73M
Shares Out	100.29M
EPS (ttm)	-0.30
PE Ratio	n/a
Forward PE	161.18
Dividend	n/a
Ex-Dividend Date	n/a

Volume	53,301
Average Volume	63,041
Open	5.50
Previous Close	5.48
Day's Range	5.50 - 5.56
52-Week Range	5.09 - 6.23
Beta	0.48
RSI	59.84
Earnings Date	Mar 21, 2025

About Knight Therapeutics

Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Ne...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2013
• Employees: 725
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: GUD

Financial Performance

In 2023, Knight Therapeutics's revenue was 328.20 million, an increase of 11.80% compared to the previous year's 293.56 million. Losses were -16.84 million, -43.68% less than in 2022.